Myriad Genetics, Inc. (NASDAQ:MYGN) Weekly Ratings on May 16, 2018

May 16, 2018 - By Pearl Odom

Myriad Genetics, Inc. (NASDAQ:MYGN) Corporate Logo
Big Money Sentiment increased to 1.37 in 2017 Q4. It has change of 0.51, from 2017Q3’s 0.86. The ratio improved due to Myriad Genetics, Inc. positioning: 19 sold and 67 reduced. 46 funds took positions and 72 increased positions. Investors holded 71.79 million in 2017Q3 but now own 71.43 million shares or 0.51% less.
Metropolitan Life Insurance Ny reported 20,446 shs. Cornerstone Capital Holding reported 27,502 shs. California Pub Employees Retirement System holds 0.01% or 318,617 shs in its capital. The Kansas-based Creative Planning has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Cubist Systematic Strategies Llc holds 0.01% or 6,229 shs in its capital. First Mercantile Tru owns 0.04% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 6,501 shs. Canada Pension Plan Inv Board has invested 0.04% of its capital in Myriad Genetics, Inc. (NASDAQ:MYGN). Guggenheim Cap Llc, Illinois-based fund reported 372,103 shs. State Teachers Retirement Sys holds 0% or 47,731 shs in its capital. Manufacturers Life Insurance Communication The reported 49,513 shs. White Pine Ltd invested 0.13% in Myriad Genetics, Inc. (NASDAQ:MYGN). Hall Laurie J Trustee reported 0% stake. The New York-based Bamco Inc New York has invested 0.03% in Myriad Genetics, Inc. (NASDAQ:MYGN). Voya Investment Mngmt Limited accumulated 40,043 shs. 160,388 are owned by Tiaa Cref Invest Mgmt Ltd Co.

Myriad Genetics, Inc. had 7 insider sales and 0 buys since December 11, 2017. This’s net activity of $5.48 million. $1.52M worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shs were sold by MARSH RICHARD M. 7,500 shs were sold by GILBERT WALTER PHD, worth $248,925 on Thursday, December 14. $201,000 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) shs were sold by DREISMANN HEINRICH.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Total analysts of 8 have positions in Myriad Genetics (NASDAQ:MYGN) as follows: 2 rated it a “Buy”, 1 with “Sell” and 5 with “Hold”. The positive are 25%. Since January 2, 2018 according to StockzIntelligence Inc Myriad Genetics has 12 analyst reports. On Wednesday, February 7 the company was maintained by Leerink Swann. On Wednesday, March 21 the stock has “Equal-Weight” rating by Morgan Stanley. On Monday, January 22 Barclays Capital maintained the shares of MYGN in report with “Hold” rating. On Tuesday, January 2 the firm has “Buy” rating given by Stephens. On Wednesday, May 9 the firm has “Equal-Weight” rating by Morgan Stanley given. On Wednesday, February 7 the stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Hold” rating by Jefferies. In Tuesday, February 6 report Piper Jaffray maintained it with “Hold” rating and $31.0 target. On Wednesday, February 7 the firm earned “Underweight” rating by Morgan Stanley. On Wednesday, February 7 the firm has “Buy” rating by BTIG Research given. Listed here are Myriad Genetics, Inc. (NASDAQ:MYGN) PTs and latest ratings.

09/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $33 New Target: $35 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Equal-Weight Old Target: $28 Upgrade
07/02/2018 Broker: BTIG Research Rating: Buy New Target: $44.0 Maintain
07/02/2018 Broker: Jefferies Rating: Hold New Target: $35.0 Maintain
07/02/2018 Broker: Leerink Swann Old Rating: Market Perform New Rating: Market Perform Old Target: $33 New Target: $35 Maintain
07/02/2018 Broker: Morgan Stanley Old Rating: Underweight New Rating: Underweight Old Target: $26 New Target: $28 Maintain
06/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $31.0 Maintain
29/01/2018 Broker: Goldman Sachs Rating: Sell New Target: $32 Initiates Coverage On
22/01/2018 Broker: Barclays Capital Rating: Hold New Target: $35.0 Maintain
16/01/2018 Broker: BTIG Research Rating: Buy New Target: $41.0

MYGN reached $34.99 during the last trading session after $1.17 change.Currently Myriad Genetics, Inc. is uptrending after 52.68% change in last May 16, 2017. MYGN has 393,104 shares volume. The stock outperformed the S&P500 by 41.13%.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.The company has $2.45 billion market cap. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.18.77 is the P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

For more Myriad Genetics, Inc. (NASDAQ:MYGN) news released recently go to: Prnewswire.com, Globenewswire.com, Businesswire.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad …” released on May 16, 2018, “SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100000 From …” on April 26, 2018, “MYGN EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Myriad …” with a publish date: May 10, 2018, “Kaskela Law LLC: Shareholder Class Action Filed Against Myriad Genetics, Inc. – MYGN” and the last “Myriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian …” with publication date: May 04, 2018.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: